CHRNChronoScale Corporation

$21.19

Price

$21.19+554%1Y
1M+5.1%1Y+554%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Lagging
2/10
Value31
Quality4
Momentum92
Growth3
Strongest Momentum, weakest Growth · ranked vs Technology peers. The five questions below judge the company on its own terms.
What they do

Founded in 2005, we are a Nevada corporation that designs, develops, and markets exoskeleton products that augment human strength, endurance and mobility. The primary end market for our exoskeleton technology is healthcare, where our technology primarily serves people with physical disabilities or impairments in both physical rehabilitation and mobility. The majority of our sales are generated from our Enterprise Health products, which includes the sales of products and services related to neurorehabilitation in clinical settings.

In the company’s own words · 10-K filed Feb 23, 2026 · SEC EDGAR

P/E (TTM)-
Market Cap$3.22B
1Y Return+554%
5Y Return-72%

Business segments

Q1 2026 · $1.8M

The company’s own SEC segment disclosure.

  • United States$1.5M87%
  • France$207.0K12%
  • Italy$26.0K1%

ChronoScale Corporation (CHRN) reported revenue of $2.1M in Q1 2026 (quarter ended Mar 31, 2026), down 37% from the same quarter a year earlier. That came with a gross margin of 50% and net loss of $6.9M. For the full year FY2025, revenue was $13M (−29% year on year) and net income −$12M. Its largest region in Q1 2026 was United States at $1.5M, 87% of the disclosed total, well ahead of France at 12%.

Raw charts

10 series · TTM

As reported to the SEC, without any scoring.